Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05514054 · ClinicalTrials.gov registry record · Phase 3
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
A Phase 3 study of Breast Neoplasms, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 8,000
- Enrollment target
- 20
- Study locations
NCT05514054 is a Phase 3 study of Breast Neoplasms that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 8,000 participants, above the 487-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (1543% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT05514054, a Phase 3 study of Breast Neoplasms, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 8,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
Conditions Studied
Interventions
- DRUG Tamoxifen
- DRUG Anastrozole
- DRUG Letrozole
- DRUG Exemestane
- DRUG Imlunestrant
Study Locations (20)
California
- UCSF - John Muir Health Cancer Center Berkeley - Berkeley
- Washington Health - Fremont
- Chao Family Comprehensive Cancer Center and Ambulatory Care (CIACC) - Irvine - Irvine
- Loma Linda University Cancer Center - Loma Linda
- Pacific Cancer Care - Monterey
- St. Joseph Hospital - Orange
- University of California, Irvine (UCI) Health - UC Irvine Medical Center - Orange
- University of California Davis (UC Davis) Comprehensive Cancer Center - Sacramento
- Kaiser Permanente San Diego Mission Road - San Diego
- Zuckerberg San Francisco General Hospital and Trauma Center - San Francisco
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- USO - Arizona Oncology Associates - HAL - Glendale
- St. Joseph's Hospital and Medical Center - Phoenix
- Mayo Clinic in Arizona - Phoenix - Phoenix
- TMC HealthCare - Tucson
- The University of Arizona Cancer Center - North Campus - Tucson
Alabama
- USO - Southern Cancer Center - Daphne
- Clearview Cancer Institute - Huntsville
- Infirmary Cancer Care - Mobile
Arkansas
- Highlands Oncology Group - Springdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,000 participants |
| Start Date | 2022-10-04 |
| Est. Completion | 2032-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05514054
The ClinicalTrials.gov registry entry for NCT05514054 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 8,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 487-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (1543% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Tamoxifen is the first listed.
NCT05514054 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT05514054 about?
NCT05514054 is a clinical study titled "A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer". The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for ...
What is the current status of trial NCT05514054?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 8,000 participants. The study started on 2022-10-04. Estimated completion is 2032-03.
What conditions does trial NCT05514054 study?
This clinical trial studies the following conditions: Breast Neoplasms.
What interventions are being tested in trial NCT05514054?
The interventions under investigation include: Tamoxifen (DRUG), Anastrozole (DRUG), Letrozole (DRUG), Exemestane (DRUG), Imlunestrant (DRUG).
Who is sponsoring clinical trial NCT05514054?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05514054 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RECRUITING · Phase 3
-
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RECRUITING · Phase 3
-
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
RECRUITING · Phase 3
-
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
RECRUITING · Phase 3
-
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
RECRUITING · Phase 3
-
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.